In this study, the patients will randomly receive either Promacta/Vidaza combination every 28 days for at least 6 cycles, or placebo plus Vidaza. The primary endpoint of the study is to compare the ...

Promacta is available in both tablet and liquid suspension forms, with dosages varying based on the specific blood disorder being treated. But, it’s typically taken once per day. When taking Promacta, ...

GlaxoSmithKline and the FDA notified healthcare professionals of a new safety finding in patients with thrombocytopenia due to chronic liver disease treated with Promacta (eltrombopag tablets). The ...

Recently, the FDA granted a breakthrough therapy designation to eltrombopag (Promacta, Novartis) for combination use with standard immunosuppressive therapy as a first-line treatment for patients with ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

First supportive care treatment approved for patients with thrombocytopenia with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy LONDON, Nov. 19, 2012 ...

GlaxoSmithKline (NYSE:GSK) now wants approval to use its low platelet drug Promacta to treat hepatitis C patients. The British pharmaceutical giant, which has its U.S. headquarters in Research ...

Promacta (eltrombopag) is a brand-name drug prescribed for certain blood conditions. Promacta has interactions with some supplements and drugs. Examples include some antacids and certain statins. An ...

Novartis announced that the Food and Drug Administration (FDA) has approved Promacta (eltrombopag) for the treatment of thrombocytopenia in children >1 year of age with chronic immune thrombocytopenia ...

The company is recalling the lots because of possible peanut flour contamination. Novartis announced on May 11, 2019 that it was recalling three lots of Promacta (eltrombopag) 12.5 mg for oral ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted breakthrough therapy designation to eltrombopag in combination with standard immunosuppressive ...